Loading...

UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Shauna Farr-Jones, PhD

Title(s)Academic Coordinator III, Anesthesia
SchoolSchool of Medicine
Phone415-754-8091
ORCID ORCID Icon0000-0003-4130-6332 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Tufts University, Boston, MAPh.D.06/1989Biochemistry
    University of Southampton, Southampton, UKBSc(Hons)6/1980Chemistry

    Collapse Research 
    Collapse Research Activities and Funding
    Antibody Technology Reseach Center
    NIH/NCI P41CA196276Sep 24, 2014 - Aug 31, 2019
    Role: Co-Investigator
    Role Description: Project Manager
    BROAD SPECTRUM MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR BOTULISM
    NIH 272201100031C-4-0-1Sep 30, 2011 - Sep 30, 2016
    Role: Co-Investigator
    BROAD SPECTRUM MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR BOTULISM
    NIH 272201100031C-1-0-1Sep 27, 2011 - Aug 1, 2015
    Role: Co-Investigator
    BROAD SPECTRUM MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR BOTULISM
    NIH 272201100031C-0-0-1Sep 27, 2011 - Sep 29, 2014
    Role: Co-Investigator
    Resource for Biocomputing, Visualization, and Informatics
    NIH/NCRR P41RR001081Jun 1, 1976 - Sep 14, 2012
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Faculty Mentoring
    Collapse Featured Presentations

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Harel ET, Drake PM, Barfield RM, Lui I, Farr-Jones S, Van't Veer L, Gartner ZJ, Green EM, Lourenço AL, Cheng Y, Hann BC, Rabuka D, Craik CS. Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer. Antibodies (Basel). 2019 Nov 05; 8(4). PMID: 31694242.
      View in: PubMed
    2. Espinoza Y, Wong D, Ahene A, Der K, Martinez Z, Pham J, Cobb RR, Farr-Jones S, Marks JD, Tomic MT. Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats. Toxins (Basel). 2019 06 17; 11(6). PMID: 31212950.
      View in: PubMed
    3. Tomic MT, Espinoza Y, Martinez Z, Pham K, Cobb RR, Snow DM, Earnhart CG, Pals T, Syar ES, Niemuth N, Kobs DJ, Farr-Jones S, Marks JD. Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins (Basel). 2019 04 06; 11(4). PMID: 30959899.
      View in: PubMed
    4. Li M, Lee D, Obi CR, Freeberg JK, Farr-Jones S, Tomic MT. An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E. PLoS One. 2018; 13(5):e0197011. PMID: 29746518.
      View in: PubMed
    5. Wijesuriya SD, Pongo E, Tomic M, Zhang F, Garcia-Rodriquez C, Conrad F, Farr-Jones S, Marks JD, Horwitz AH. Antibody engineering to improve manufacturability. Protein Expr Purif. 2018 09; 149:75-83. PMID: 29655788.
      View in: PubMed
    6. Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD. A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes. Toxins (Basel). 2018 03 01; 10(3). PMID: 29494481.
      View in: PubMed
    7. Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD. A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. Toxins (Basel). 2018 02 15; 10(2). PMID: 29462889.
      View in: PubMed
    8. Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD. Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel. 2018 01 01; 31(1):17-28. PMID: 29301020.
      View in: PubMed
    9. Fox S, Farr-Jones S, Sopchak L, Boggs A, Nicely HW, Khoury R, Biros M. High-throughput screening: update on practices and success. J Biomol Screen. 2006 Oct; 11(7):864-9. PMID: 16973922.
      View in: PubMed
    10. Fox S, Farr-Jones S, Sopchak L, Boggs A, Comley J. High-throughput screening: searching for higher productivity. J Biomol Screen. 2004 Jun; 9(4):354-8. PMID: 15191652.
      View in: PubMed
    11. Fox S, Wang H, Sopchak L, Farr-Jones S. High throughput screening 2002: moving toward increased success rates. J Biomol Screen. 2002 Aug; 7(4):313-6. PMID: 12230884.
      View in: PubMed
    12. Farr-Jones S. Business and science of proteomics--third annual event. Next-generation technologies for high-throughput proteomics. IDrugs. 2001 Nov; 4(11):1235-6. PMID: 15942822.
      View in: PubMed
    13. Avizonis D, Farr-Jones S. The Internet for nuclear magnetic resonance spectroscopists. Methods Enzymol. 2001; 338:247-57. PMID: 11460551.
      View in: PubMed
    14. Farr-Jones S. Chemokine antagonists as anti-inflammatory and antiviral agents II. IDrugs. 2000 Jun; 3(6):584-5. PMID: 16096911.
      View in: PubMed
    15. Liu H, Farr-Jones S, Ulyanov NB, Llinas M, Marqusee S, Groth D, Cohen FE, Prusiner SB, James TL. Solution structure of Syrian hamster prion protein rPrP(90-231). Biochemistry. 1999 Apr 27; 38(17):5362-77. PMID: 10220323.
      View in: PubMed
    16. Fox S, Farr-Jones S, Yund MA. High Throughput Screening for Drug Discovery: Continually Transitioning into New Technology. J Biomol Screen. 1999; 4(4):183-186. PMID: 10838437.
      View in: PubMed
    17. Armand P, Kirshenbaum K, Goldsmith RA, Farr-Jones S, Barron AE, Truong KT, Dill KA, Mierke DF, Cohen FE, Zuckermann RN, Bradley EK. NMR determination of the major solution conformation of a peptoid pentamer with chiral side chains. Proc Natl Acad Sci U S A. 1998 Apr 14; 95(8):4309-14. PMID: 9539733.
      View in: PubMed
    18. James TL, Liu H, Ulyanov NB, Farr-Jones S, Zhang H, Donne DG, Kaneko K, Groth D, Mehlhorn I, Prusiner SB, Cohen FE. Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. Proc Natl Acad Sci U S A. 1997 Sep 16; 94(19):10086-91. PMID: 9294167.
      View in: PubMed
    19. Farr-Jones S, Miljanich GP, Nadasdi L, Ramachandran J, Basus VJ. Solution structure of omega-conotoxin MVIIC, a high affinity ligand of P-type calcium channels, using 1H NMR spectroscopy and complete relaxation matrix analysis. J Mol Biol. 1995 Apr 21; 248(1):106-24. PMID: 7731037.
      View in: PubMed
    20. Hedstrom L, Farr-Jones S, Kettner CA, Rutter WJ. Converting trypsin to chymotrypsin: ground-state binding does not determine substrate specificity. Biochemistry. 1994 Jul 26; 33(29):8764-9. PMID: 8038166.
      View in: PubMed
    21. Farr-Jones S, Smith SO, Kettner CA, Griffin RG, Bachovchin WW. Crystal versus solution structure of enzymes: NMR spectroscopy of a peptide boronic acid-serine protease complex in the crystalline state. Proc Natl Acad Sci U S A. 1989 Sep; 86(18):6922-4. PMID: 2780549.
      View in: PubMed
    22. Smith SO, Farr-Jones S, Griffin RG, Bachovchin WW. Crystal versus solution structures of enzymes: NMR spectroscopy of a crystalline serine protease. Science. 1989 May 26; 244(4907):961-4. PMID: 2499045.
      View in: PubMed
    23. Bachovchin WW, Wong WY, Farr-Jones S, Shenvi AB, Kettner CA. Nitrogen-15 NMR spectroscopy of the catalytic-triad histidine of a serine protease in peptide boronic acid inhibitor complexes. Biochemistry. 1988 Oct 04; 27(20):7689-97. PMID: 3207700.
      View in: PubMed